Atopic dermatitis: Tofacitinib, an option for refractory disease

Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate‐severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Berbert Ferreira, Sineida, Berbert Ferreira, Rachel, Scheinberg, Morton Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752607/
https://www.ncbi.nlm.nih.gov/pubmed/33363913
http://dx.doi.org/10.1002/ccr3.3325
_version_ 1783625901905281024
author Berbert Ferreira, Sineida
Berbert Ferreira, Rachel
Scheinberg, Morton Aaron
author_facet Berbert Ferreira, Sineida
Berbert Ferreira, Rachel
Scheinberg, Morton Aaron
author_sort Berbert Ferreira, Sineida
collection PubMed
description Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate‐severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.
format Online
Article
Text
id pubmed-7752607
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77526072020-12-23 Atopic dermatitis: Tofacitinib, an option for refractory disease Berbert Ferreira, Sineida Berbert Ferreira, Rachel Scheinberg, Morton Aaron Clin Case Rep Case Reports Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate‐severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response. John Wiley and Sons Inc. 2020-10-11 /pmc/articles/PMC7752607/ /pubmed/33363913 http://dx.doi.org/10.1002/ccr3.3325 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Berbert Ferreira, Sineida
Berbert Ferreira, Rachel
Scheinberg, Morton Aaron
Atopic dermatitis: Tofacitinib, an option for refractory disease
title Atopic dermatitis: Tofacitinib, an option for refractory disease
title_full Atopic dermatitis: Tofacitinib, an option for refractory disease
title_fullStr Atopic dermatitis: Tofacitinib, an option for refractory disease
title_full_unstemmed Atopic dermatitis: Tofacitinib, an option for refractory disease
title_short Atopic dermatitis: Tofacitinib, an option for refractory disease
title_sort atopic dermatitis: tofacitinib, an option for refractory disease
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752607/
https://www.ncbi.nlm.nih.gov/pubmed/33363913
http://dx.doi.org/10.1002/ccr3.3325
work_keys_str_mv AT berbertferreirasineida atopicdermatitistofacitinibanoptionforrefractorydisease
AT berbertferreirarachel atopicdermatitistofacitinibanoptionforrefractorydisease
AT scheinbergmortonaaron atopicdermatitistofacitinibanoptionforrefractorydisease

Ejemplares similares